Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10555-10561

  Rossi, Gabriela R ^a,b   Mautino, Mario R ^a   Unfer, Robert C ^b   Seregina, Tatiana M ^a,b   Vahanian, Nicholas ^a   Link, Charles J ^a,b  

^a NEWLINK GENETICS   (United States)

^b Iowa Cancer Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYL; ALPHA 1,3 GALACTOSYLTRANSFERASE; CANCER VACCINE; GALACTOSYLTRANSFERASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MODEL; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNE RESPONSE; KNOCKOUT MOUSE; LUNG METASTASIS; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINE PRODUCTION; WHOLE CELL; XENOGRAFT;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES; TRISACCHARIDES;

EID: 28544437092     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0627     Document Type: Article

References (33)

1. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-25.
2. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269-77.
3. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
4. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-gal:β-D-gal(1,4)-D-GlcNAc α(1,3)- galactosyltransferase cDNA. J Biol Chem 1990;265:7055-61.
5. Joziasse DH, Oriol R. Xenotransplantation: the importance of the Galα1,3Gal epitope in hyperacute vascular rejection. Biochim Biophys Acta 1999;1455:403-18.
6. Baumann BC, Forte P, Hawley RJ, Rieben R, Schneider MK, Seebach JD. Lack of galactose-α-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 2004;172:6460-7.
7. Schaapherder AF, Doha MR, te Bulte MT, van der Woude FJ, Gooszen HG. Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 1994;57:1376-82.
8. Watier H, Guillaumin JM, Vallee I, et al. Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol 1996;4:293-9.
9. Watier H, Guillaumin JM, Piller F, et al. Removal of terminal α-galactosyl residues from xenogeneic porcine endothelial cells. Decrease in complement-mediated cytotoxicity but persistence of IgG1-mediated antibody-dependent cell-mediated cytotoxicity. Transplantation 1996;62:105-13.
10. Link CJ, Jr., Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: α(1,3) galactosyltransferase gene therapy. Anticancer Res 1998;18:2301-8.
11. Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997;18:281-5.
12. Galili U. Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother 2004;53:935-45.
13. Posekany KJ, Pittman HK, Swanson MS, Haisch CE, Verbanac KM. Suppression of Lewis lung tumor development in α 1,3 galactosyltransferase knock-out mice. Anticancer Res 2004;24:605-12.
14. Rossi GR, Unfer RC, Seregina T, Link CJ. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes. Cancer Immunol Immunother 2005;54:999-1009.
15. Thall AD, Maly P, Lowe JB. Oocyte Gal α 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 1995;270:21437-40.
16. Xu H, Sharma A, Chen L, et al. The structure of anti-Gal immunoglobulin genes in naive and stimulated Gal knockout mice. Transplantation 2001;72:1817-25.
17. Posekany KJ, Pittman HK, Bradfield JF, Haisch CE, Verbanac KM. Induction of cytolytic anti-Gal antibodies in α-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria. Infect Immun 2002;70:6215-22.
18. Unfer RC, Hellrung D, Link CJ, Jr. Immunity to the α(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing α(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res 2003;63:987-93.
19. LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 1999;59:3417-23.
20. Gorelik E, Duty L, Anaraki F, Galili U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α 1,3 galactosyltransferase gene transfection. Cancer Res 1995;55:4168-73.
21. Rosenberg SA. Principles and practice of the biologic therapy of cancer, 3rd ed. PA: Lippincott Williams & Wilkins; 2000.
22. Link CJ, Hellrung DJ, Seregina T, Wang S. Eliciting hyperacute rejection as a tumor killing strategy. Herpes amplicon vector transfer of the α(1,3)galactosyltransfer-(1,3)galactosyltransferase gene. Adv Exp Med Biol 2000;465:217-27.
23. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of α-galactosyl epitopes by recombinant α1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996;56:3069-74.
24. + CTL responses in vivo. J Immunol 2002;168:2240-6.
25. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
26. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
27. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
28. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76.
29. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
30. + T-cell responses. Nat Med 2003;9:1287-92.
31. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003;3:472-82.
32. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099-103.
33. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.